Venous Thrombosis Recurrence After Catheter-Related Upper Extremity Deep Venous Thrombosis in Cancer Patients: A Retrospective Analysis.

Autor:	Hakem R; Department of Vascular Medicine, Amiens-Picardie University Hospital, Amiens, France., Soudet S; Department of Vascular Medicine, Amiens-Picardie University Hospital, Amiens, France.; EA CHIMERE, Picardie Jules Verne University, Amiens, France., Diouf M; DRCI, Amiens-Picardie University Hospital, Amiens, France., Sevestre MA; Department of Vascular Medicine, Amiens-Picardie University Hospital, Amiens, France.; EA CHIMERE, Picardie Jules Verne University, Amiens, France.
Jazyk:	angličtina
Zdroj:	Angiology [Angiology] 2024 Aug; Vol. 75 (7), pp. 658-665. Date of Electronic Publication: 2023 May 17.
DOI:	10.1177/00033197231176985
Abstrakt:	Long-term indwelling central venous catheters (CVC) are frequently used to secure vascular access to deliver injectable treatment. Catheter-related thrombosis (CRT) occurs in approximately 2-6% of cancer patients. We conducted a single-center retrospective study to assess the rate of venous thromboembolism (VTE) recurrence in cancer patients; 200 patients were included. Mean age was 56 ± 15.15 years, median follow-up duration was 16.5 [range: 10-36] months. The incidence of recurrence was estimated using Gray's method for competing risk with death as the competing event of VTE. Recurrent VTE occurred in 25.5% of patients with a median occurrence time of 6.5 [range: 5-11.25] months. In case of recurrence, 94.6% of patients were treated for cancer and 80.4% of them received anticoagulants; 4 major bleeds and 17 non-major bleeds occurred during follow-up. In multivariate analysis, previous VTE (Hazard Ratio (HR) 2.48 (95% CI 1.42-4.32) and presence of CVC (HR 5.56 (95% CI 1.96-15.75) were significant recurrence risk factors. After a first episode of CRT, 25.5% of patients experienced VTE recurrence as UEDVT in 30 cases (55.5%), PE in 17 cases (31.5%), and DVT in 7 cases (13%), mostly during anticoagulation therapy. Anticoagulation therapy does not avoid CRT in case of cancer and must be balanced with hemorrhagic risk. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All authors state the absence of potential conflict of interest for this publication.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu